Literature DB >> 31863228

Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.

Yong-Il Shin1, Kyeung-Min Kim1, Min-Woo Lee1, Jung-Yeul Kim1, Young-Joon Jo2.   

Abstract

PURPOSE: To evaluate the long-term results of focal laser photocoagulation and photodynamic therapy (PDT) for treatment of central serous chorioretinopathy (CSC). STUDY
DESIGN: Retrospective chart review.
METHODS: Sixty-two patients with CSC, thirty-three of whom were treated with focal laser photocoagulation, and 29 with PDT and who were followed up for > 6 months, were enrolled. The focal laser was performed at sites of focal leakage (but not subfoveal leaks) shown in fluorescein angiography. PDT was performed at sites of subfoveal or juxtafoveal focal leakage or not definite focal leakages. Best corrected visual acuity (BCVA), central macular thickness (CMT), resolution of subretinal fluid (SRF) and recurrence were analyzed.
RESULTS: The follow-up duration of the focal laser group was 35.2 ± 22.6 and of the PDT group, 46.4 ± 21.5 months. Time to resolution of SRF was 1.8 ± 1.5 months for the focal laser group and 1.2 ± 0.5 months for the PDT group. SRF was rapidly absorbed in the PDT group. In both groups, the CMT was decreased 1 month after treatment. The BCVA improved significantly 1 month after treatment in the focal laser group and 3 months after treatment in the PDT group. However, there was no significant difference in CMT reduction and BCVA improvement between the two groups. It subsequently remained similar for up to 3 years. Ten patients (30.3%) in the focal laser group and three patients (10%) in the PDT group recurred during the follow-up period.
CONCLUSIONS: PDT showed early resolution of the SRF compared to focal laser. In CSC patients, both the CMT and BCVA remained stable for 3 years after treatment. After 3 or more years of follow-up, PDT showed a lower recurrence rate than focal laser.

Entities:  

Keywords:  Central serous chorioretinopathy; Focal laser photocoagulation; Long-term results; Photodynamic therapy; Recurrence

Mesh:

Substances:

Year:  2019        PMID: 31863228     DOI: 10.1007/s10384-019-00697-0

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  34 in total

1.  Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.

Authors:  Maiko Inoue; Kazuaki Kadonosono; Yoichiro Watanabe; Satoshi Kobayashi; Shin Yamane; Akira Arakawa
Journal:  Ophthalmologica       Date:  2010-08-07       Impact factor: 3.250

2.  Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy.

Authors:  Michael Colucciello
Journal:  Retina       Date:  2006-02       Impact factor: 4.256

3.  Acute central serous chorioretinopathy and fundus autofluorescence.

Authors:  Chiara M Eandi; Michael Ober; Reza Iranmanesh; Enrico Peiretti; Lawrence A Yannuzzi
Journal:  Retina       Date:  2005-12       Impact factor: 4.256

4.  The long-term outcome of central serous chorioretinopathy.

Authors:  E Y Yap; D M Robertson
Journal:  Arch Ophthalmol       Date:  1996-06

5.  Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Alexandros Rouvas; Panagiotis Stavrakas; Panagiotis G Theodossiadis; Polyxeni Stamatiou; Maria Milia; Emmanuela Giannakaki; Ioannis Datseris
Journal:  Eur J Ophthalmol       Date:  2012 May-Jun       Impact factor: 2.597

6.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

7.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

8.  Long-term follow-up of central serous chorioretinopathy.

Authors:  C M Gilbert; S L Owens; P D Smith; S L Fine
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

9.  Photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Chiara M Eandi; Luca Ventre; Roberta C Rigault de la Longrais; Federico M Grignolo
Journal:  Retina       Date:  2003-12       Impact factor: 4.256

10.  Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.

Authors:  R Levine; A J Brucker; F Robinson
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

View more
  2 in total

1.  Regression patterns of central serous chorioretinopathy using en face optical coherence tomography.

Authors:  Supriya Arora; Brian Rosario; Abdul Rasheed Mohammed; Oliver Beale; Amrish Selvam; Ramesh Venkatesh; Dmitrii S Maltsev; Jay Chhablani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-31       Impact factor: 3.535

Review 2.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.